Tango Therapeutics appoints new CFO, additional execs to accelerate vopimetostat development

Tango Therapeutics, Inc.

Daniella Beckman departs as CFO effective April 15; Matthew Gall named successor.
Matthew Gall receives $540K base salary, 40% target bonus, 240K option shares, 40K RSUs.
Jessica Newcomb appointed principal accounting officer; Yen-Ching Chua named Chief Development Operations Officer.
Janice Kapty named SVP Corporate Strategy and Project Leadership; company focuses on vopimetostat for pancreatic cancer.
Tango plans to present key clinical data in 2026, including combination trial with Revolution Medicines' RAS(ON) inhibitors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.